Nu Skin Enterprises, Inc. filings document the company’s operating results, governance, executive leadership changes and financing arrangements. Recent 8-K reports include quarterly and annual financial-result releases, officer appointments and resignations, compensation arrangements, and material definitive agreements tied to amended credit facilities.
The company’s proxy materials provide annual meeting governance and executive-compensation disclosures, including board and compensation matters reported under Schedule 14A. Nu Skin’s regulatory record also reflects its capital structure and liquidity arrangements, including term loan and revolving credit facilities, alongside formal disclosures for its beauty and wellness operations, affiliate platform and Rhyz-related business activities.
NuSkin Enterprises, Inc. (NUS) Form 144 shows a proposed sale of 6,489 Class A shares through William Blair in Chicago, to be executed approximately on 09/04/2025 on the NYSE. The filing lists an aggregate market value of $77,868.00 and reports 49,497,715 Class A shares outstanding for the issuer.
The 6,489 shares were acquired from the issuer as compensation across annual grant dates: 04/30/2021 (422 shares), 04/30/2022 (2,467), 04/30/2023 (3,179) and 04/30/2024 (421), with matching payment dates. The filer reports no securities sold in the past three months and includes the standard attestation regarding absence of undisclosed material adverse information.
Nu Skin Enterprises (NUS) filing a Form 144 notifies the SEC of a proposed sale of 20,000 Class A shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $239,433.56 and approximately 49,497,715 Class A shares outstanding. The securities listed were acquired as restricted stock vesting from the issuer on multiple dates between 02/15/2022 and 02/15/2024, with individual lot sizes shown. The filer reports no securities sold in the past three months and affirms they possess no undisclosed material adverse information about the issuer. The notice includes required signature and legal attestation language.
Daniel W. Campbell, a director of Nu Skin Enterprises (NUS), reported open-market sales of Class A common stock on 08/29/2025. The filing shows two disposal transactions: 9,046 shares sold at a weighted-average price of $12.12 and 23,391 shares sold at a weighted-average price of $12.10, for total reported disposals of 32,437 shares. After the transactions the report shows 39,216 shares held directly and 53,375 shares held indirectly, including shares held by an irrevocable family trust and by a limited liability company controlled by the reporting person and his spouse.
Form 144 filed for NuSkin Enterprises, Inc. (NUS) reports a proposed sale of 23,391 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $283,117.65. The filing lists the approximate date of sale as 08/29/2025 and shows 49,497,715 shares outstanding. All 23,391 shares were acquired as gifts from affiliate Daniel Campbell on 11/02/2021, with donor acquisition dates and per-lot amounts totaling the 23,391 shares. The filer reports "Nothing to Report" for securities sold in the past three months and includes the standard representation that no undisclosed material adverse information about the issuer is known.
Nu Skin Enterprises (NUS) Form 144 filing reports a proposed sale of 9,046 shares of Common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $109,635.71. The shares represent restricted stock that vested under the issuer's registered plan on 04/24/2012 (4,046 shares) and 05/24/2018 (5,000 shares), with cash payment recorded on the respective vesting dates. The filer states there were no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.